Skrizi May Lead to Clinical Improvements
In a recent study completed by AbbVie, data from two Phase 3 induction studies demonstrates Skyrizi (risankizumab) can lead to clinical improvements in patients diagnosed with moderate to severe Crohn’s disease.
On January 7th, AbbVie, the biopharmaceutical company that created Humira, announced positive results from two of their Phase 3 induction studies, ADVANCE and MOTIVATE. Those results suggested that doses of risankizumab (600 mg and 1200 mg) induced clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn’s disease. The ADVANCE study consisted of patients who had an inadequate or intolerant response to conventional and/or biologic therapy. The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.
Read their full press release here: https://tinyurl.com/y3bnr5al